Receive The Newest Study Notifications

- TrialSpark partners with doctors to offer clinical trials in their existing practices by providing all the training, resources, and staff needed to run investigational and observational studies. - In collaboration with TrialSpark, Novartis is pioneering new, bespoke...

Cellular Biomedicine Group Inc.(NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announces the initiation of patient recruitment to...

Received European approval to ship Annamycin into Poland to start treating patients HOUSTON, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of...

- TrialSpark partners with doctors to offer clinical trials in their existing practices by providing all the training, resources, and staff needed to run investigational and observational studies. - In collaboration with TrialSpark, Novartis is pioneering new, bespoke...

Results Are Expected to Prompt Changes in Practice, Improve Patient Outcomes Three studies being presented today during the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego offer more targeted solutions for managing CLL and multiple...

Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) today announced that it has passed the 50 percent enrollment point in its first pivotal Phase 3 clinical trial of RP-G28 for the potential treatment of LI, a study known as the “Liberatus” study. “We are pleased to have...

New tools and approaches poised to improve diagnostics and care for millions worldwide Four late-breaking studies being presented today during the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego offer groundbreaking solutions to...

Sixgill, LLC, the leader in sensor data services for governing Internet of Everything (IoE) assets, today announced Litmus Health will adopt Sixgill Integrity to provide blockchain data accuracy and consistency for its clinical data science platform. The combination...

Atlanta-based FusionHealth announced today a new research collaboration with the University of Michigan for a clinical trial called Sleep SMART (Sleep for Stroke Management and Recovery Trial), during which researchers will investigate whether obstructive sleep apnea...

Grant funding by The Michael J. Fox Foundation will support Phase 2 trial Alkahest, Inc., a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced dosing of the first subject in a Phase 2 clinical...

Trialbee, a global provider of best-in-class digital patient recruitment and engagement solutions for clinical research, announces the official release of its digital patient engagement solutions. With Trialbee, sponsors, CROs and investigator sites can increase...

Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, announced today that the Company has dosed its first patient for its bioequivalence study of Tadalafil (Cialis®) and Finasteride (PROSCAR®) combination tablet for benign prostatic hyperplasia...

Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that patient enrollment in the ongoing Phase 2a clinical trial...

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced initial clinical data from cohorts in its ongoing Phase 2 trial evaluating SY-1425, its first-in-class selective retinoic acid receptor...

- 83% overall response rate, with evidence of deepening of response over time - - Median duration of response not reached; 12-month duration of response rate of 76% - - Statistically significant improvements in patient-reported disease symptoms observed - - 7 of 7...

Researchers plan to enroll approximately 420 couples in clinical trial. A clinical trial funded by the National Institutes of Health will evaluate a male contraceptive gel for its ability to prevent pregnancy. The gel formulation was developed by the Population...

U.S. contract research organization market accounted for 86.7% revenue share of North America in 2017 and is expected to grow considerably during the forecast year owing to growing patient concern pertaining to safety and efficacy of drugs increases demand for CRO...

43% CR/CRi/CRp rate with bemcentinib monotherapy reported in AXL biomarker positive R/R AML/MDS patients (6 out of 14) Phase II trial continues in combination with chemotherapeutics in first line AML Bemcentinib with decitabine cohort has completed recruitment, data...

The Cancer Research Institute (CRI), a nonprofit organization dedicated to the discovery and development of powerful immunotherapies for all cancers, announced today the publication of a report that provides a comprehensive analysis of the current clinical trial...